GENEWIZ, Inc., a leading provider of DNA services, announced the expansion of its molecular biology portfolio with the addition of Gene Synthesis services.
Gene synthesis provides researchers with a time- and cost-saving alternative to molecular cloning, DNA engineering, protein engineering and directed evolution for custom construct production.
GENEWIZ's expertise allows synthesizing genes of varying complexities with extremely high success rates, spanning short genes to long, 50-kb genes and difficult genes with repetitive sequences, high GC-content, or secondary structures. Institutional partnership agreements have been executed with major pharmaceutical and biotechnology companies. "We very much respect the trust that our DNA sequencing customers have placed in us, and are grateful that they have extended that trust to our gene synthesis services," stated Ping Yang, Ph.D., GENEWIZ Business Leader for Gene Synthesis. "We are proud to support our customers' DNA innovations in such important fields as biofuels, nanotechnology, protein and antibody engineering, vaccines, and gene therapy. We have experienced widespread customer adoption beyond our expectations by academic, pharmaceutical, biotechnology, and government researchers."
GENEWIZ focuses on supporting its gene synthesis customers with excellent project managers, all with deep technical expertise. The gene synthesis service offering includes competitive prices, comprehensive project management and fast turnaround times. Difficult genes require longer turnaround times; GENEWIZ has synthesized and delivered difficult genes that were refused by or failed with other service providers. All synthesized genes are sequence-verified.
Marc Schwartz, Ph.D., GENEWIZ Project Manager for gene synthesis, noted, "Outsourcing of bio-reagent construction is often favored as a cost-saving approach. Our customers benefit from our specialized expertise, 10-year track record of superior project management, and stringent quality assurance system."